Molecular Therapy – Methods & Clinical Development, 2017
Safe by design. Built for the clinic. NIMVEC’s proprietary SVac® platform overcomes one of the key challenges in SV40 vector technology by enabling the production of replication-defective viral vectors without replication-competent contaminants. Designed for safety, scalability, and immune tolerance, SVac® opens the door to a new generation of gene therapies for autoimmune, genetic, and other complex diseases.
